Literature DB >> 32107215

Choosing antithrombotics for atrial fibrillation in primary care.

Mohammed Mustafa1, James P Sheppard2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32107215      PMCID： PMC7038865          DOI： 10.3399/bjgp20X708317

Source DB:  PubMed          Journal:  Br J Gen Pract        ISSN： 0960-1643            Impact factor:   5.386


× No keyword cloud information.
  16 in total

Review 1.  Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis.

Authors:  George Ntaios; Vasileios Papavasileiou; Konstantinos Makaritsis; Konstantinos Vemmos; Patrik Michel; Gregory Y H Lip
Journal:  Stroke       Date:  2017-07-17       Impact factor: 7.914

2.  Adherence with oral anticoagulation in non-valvular atrial fibrillation: a comparison of vitamin K antagonists and non-vitamin K antagonists.

Authors:  Rikke Sørensen; Berit Jamie Nielsen; Jannik Langtved Pallisgaard; Christina Ji-Young Lee; Christian Torp-Pedersen
Journal:  Eur Heart J Cardiovasc Pharmacother       Date:  2017-07-01

3.  A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study.

Authors:  F D R Hobbs; D A Fitzmaurice; J Mant; E Murray; S Jowett; S Bryan; J Raftery; M Davies; G Lip
Journal:  Health Technol Assess       Date:  2005-10       Impact factor: 4.014

4.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.

Authors:  Paulus Kirchhof; Stefano Benussi; Dipak Kotecha; Anders Ahlsson; Dan Atar; Barbara Casadei; Manuel Castella; Hans-Christoph Diener; Hein Heidbuchel; Jeroen Hendriks; Gerhard Hindricks; Antonis S Manolis; Jonas Oldgren; Bogdan Alexandru Popescu; Ulrich Schotten; Bart Van Putte; Panagiotis Vardas
Journal:  Eur Heart J       Date:  2016-08-27       Impact factor: 29.983

5.  Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.

Authors:  Morten L Hansen; Rikke Sørensen; Mette T Clausen; Marie Louise Fog-Petersen; Jakob Raunsø; Niels Gadsbøll; Gunnar H Gislason; Fredrik Folke; Søren S Andersen; Tina K Schramm; Steen Z Abildstrøm; Henrik E Poulsen; Lars Køber; Christian Torp-Pedersen
Journal:  Arch Intern Med       Date:  2010-09-13

6.  Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.

Authors:  Robert G Hart; Lesly A Pearce; Maria I Aguilar
Journal:  Ann Intern Med       Date:  2007-06-19       Impact factor: 25.391

7.  Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study.

Authors:  Carlos Martinez; Anja Katholing; Christopher Wallenhorst; Saul Benedict Freedman
Journal:  Thromb Haemost       Date:  2015-08-06       Impact factor: 5.249

Review 8.  Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis.

Authors:  José A López-López; Jonathan A C Sterne; Howard H Z Thom; Julian P T Higgins; Aroon D Hingorani; George N Okoli; Philippa A Davies; Pritesh N Bodalia; Peter A Bryden; Nicky J Welton; William Hollingworth; Deborah M Caldwell; Jelena Savović; Sofia Dias; Chris Salisbury; Diane Eaton; Annya Stephens-Boal; Reecha Sofat
Journal:  BMJ       Date:  2017-11-28

9.  Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care.

Authors:  Yana Vinogradova; Carol Coupland; Trevor Hill; Julia Hippisley-Cox
Journal:  BMJ       Date:  2018-07-04

10.  Safety and Effectiveness of Contemporary P2Y12 Inhibitors in an East Asian Population With Acute Coronary Syndrome: A Nationwide Population-Based Cohort Study.

Authors:  Ji Eun Yun; Yun Jung Kim; Ji Jeong Park; Sehee Kim; Keunhui Park; Min Soo Cho; Gi-Byoung Nam; Duk-Woo Park
Journal:  J Am Heart Assoc       Date:  2019-07-16       Impact factor: 5.501
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.